Vera Therapeutics

Q2 FY2026 EarningsQ2 FY26 results outperformed consensus on the bottom line, reporting a diluted EPS loss of $1.52 compared to the $1.56 loss anticipated. Revenue was $0, in line with expectations, as the flagship product TRUTAKNA received FDA accelerated approval on July 7, 2026 (post-quarter end). Operating loss of $112.5M was slightly narrower than the $115.9M mean estimate, reflecting managed R&D scaling ahead of commercialization. With $499.2M in liquidity, the focus shifts to the Q3 FY26 commercial launch and the ORIGIN 3 final efficacy analysis.